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Background
The use of left ventricular assist device (LVAD) has emerged as a popular
treatment for patients with advanced heart failure. It is not uncommon for these
patients to suffer from renal failure requiring renal replacement therapy. The
purpose of this study is to assess hemodynamic parameters and ability to
complete the prescribed hemodialysis session in a series of patients who
underwent numerous dialysis treatments.
Methods
Nine patients with Heart Mate II LVAD received 170 intermittent inpatient
hemodialysis treatments between January 1, 2010 and December 31, 2012.
Assessment included vital signs, ultrafiltrate removed, hemodialysis duration,
symptoms, early terminations (ET), and adverse events during each hemodialysis
session.
Results
The mean age was 53 ± 18 with a range of 26-83 years, with a male
predominance (7/9). Indication for LVAD was as destination therapy (DT) in the
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majority of patients (6/9). Nine patients who received a total of 170 hemodialysis
sessions with a mean prescribed and achieved: ultrafiltration (liters) 1.98 ± 1.5 and
1.90 ± 1.6; hemodialysis duration (hours) 3.12 ± 0.3 and 2.86 ± 0.9, respectively.
Early termination was experienced in 11 sessions (6.5%). Causes of ET were
hypotension in 72.7%, other causes were equally distributed between clotted
extra-corporeal circuits, nausea & vomiting and LVAD alarm (9.1% in each).
Serious arrhythmias were not observed in any of the hemodialysis treatments. Six
out of nine patients (66.7%) recovered kidney function and became dialysis
independent.
Conclusion
In a hospital setting, patients with LVAD can often tolerate and complete the
prescribed hemodialysis treatment.
Keywords: Hemodialysis, Heart failure, Kidney failure, Hemodynamic instability,
LVAD

Introduction
Roughly 5.7 million individuals in the United States live with heart failure (HF), 10%
of which are considered to be advanced and non-responsive to conventional
therapies [1]. HF can be associated with cardio-renal syndrome; a bidirectional
and dysfunctional interaction between heart and kidneys in which therapy to
relieve HF is limited by worsening renal function [2]. In the US, over 1 million
patients are hospitalized annually for acute decompensated HF and 27-40% of
these patients develop acute kidney injury (AKI) [3]. Sixty-three percent of patients
hospitalized with congestive heart failure meet the National Kidney Foundation
Kidney Disease Outcomes Quality Initiative (K/DOQI) definition of Stage 3-5
chronic kidney disease (CKD) [4].
The number of patients with advanced heart failure that has become unresponsive
to conventional medical therapy is increasing rapidly. One of the most promising
new alternatives to heart transplantation is use of ventricular assist devices [5].
Left ventricular assist devices (LVADs) draw blood from the left ventricle and
delivers it directly into the ascending aorta. Recently, it has emerged as a common
therapy for patients with acute or chronic severe HF. It can be used as a bridge to
transplantation or as a destination therapy (i.e., for circulatory support with no
intention of transplantation). According to the Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS), more than 15,000 VAD
implants were performed between 2006 and 2015 [6]. Due to the limited number of
heart transplants that can be performed each year and the improved efficacy of
LVAD as destination therapy, LVAD implantation frequency increased
exponentially each year. For example, 206 VAD implants were performed in 2006
as compared to more than 2500 in 2013 [6].
Decompensated HF patients with renal failure may require renal replacement
therapy (RRT) until kidney function recovers. In one study, of 107 consecutive
patients who underwent HeartMate II implantation, 14% required RRT [7]. The
majority of these patients are managed on an inpatient basis which results in
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intensive nursing care and accrual of high medical cost. In 2010, Medicare
expenditures for patients with both CKD and HF totaled over $19.4 billion [8].
There is limited information in the literature about the tolerability of these patients
to intermittent hemodialysis (IHD). The purpose of this study is to describe the
experience in a cohort of patients who received LVAD and underwent a rather
large number of IHD treatments in a single medical center.

Methods
Research Design and Data Collection
Information on patient demographics, medical history, and dialysis prescriptions
were retrospectively obtained using the electronic medical record. Each IHD
session flowsheet was individually reviewed, and the following data were recorded:
blood pressure (BP), heart rate (HR), ultrafiltrate (UF) removed, dialysis duration,
and symptoms documented by nursing staff. If blood pressure could be obtained
by cuff, mean arterial pressure (MAP) was calculated as the sum of 1/3 systolic
blood pressure (SBP) and 2/3 diastolic blood pressure (DBP). Doppler assessment
of MAP was utilized in the majority of the cases [9]. Beside Doppler
measurements, the nursing staff relied on patient symptoms and the continuous
hemodynamic parameters of the LVAD apparatus for clinical assessment. HR was
assessed by reviewing the rhythm on a telemetry monitor.
All patients were dialyzed with a Gambro Revaclear dialysis membrane (Opelika,
AL) with a 2.25mEq/L calcium dialysate at 37ºC. The University of Kentucky
Institutional Review Board approved the study protocol. Consent was waived
given the retrospective nature of the study.
Participants and Settings
Patients included in the study received IHD between January 1, 2010 and
December 31, 2012, and were selected using the procedural terminology (CPT)
codes for LVAD and IHD. They were more than 18 years of age and received a
HeartMate II® left ventricular assist system (Thoratec® Corporation, Pleasanton,
CA). At the time of this study, the HeartMate II LVAD was the most commonly
used continuous-flow pump for destination therapy in HF [10].
The HeartMate II® flow setting were predetermined by the LVAD nurse and not
altered by the IHD staff. Throughout the dialysis treatment, patients were observed
via telemetry, and LVAD-parameters monitor, which included pump speed (range
8600 to 9800 rpm), power, and pulsatility-index (PI). PI, an inverse measure of
assistance provided by the continuous-flow pump, is an indicator of decreased
circulating blood volume. LVAD nurses were instructed to use the parameters,
including PI, in addition to a drop in MAP below 60 mmHg to notify the dialysis
staff of hemodynamically significant events [10].

Results
Nine patients who received a total of 170 IHD sessions were identified. The mean
age was 53 ± 18 with a range of 26-83 years, with a male predominance (7/9). The
majority of patients (6/9) did not have prior known CKD. Indication for LVAD was
as destination therapy (DT) in the majority of patients (6/9). All patients who were
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bridged-to-transplant (BTT) ultimately received cardiac transplantation (3/3). Time
to IHD post-LVAD insertion was quite varied, with only 3 patients started on IHD
within 2 weeks of implantation. Approximately 2/3 of the IHD sessions were
performed in an ICU setting. In this series the longest period of time that a patient
was maintained continuously on IHD was slightly greater than 2 months. Of
interest, the majority of patients (6/9) recovered kidney function and became
dialysis independent (Table 1). The mean pre- and post IHD systolic blood
pressures were 98 ± 13 mmHg (range: 77-116) and 98 ± 13 mmHg (range: 83119). The average blood flow rates during dialysis were 347 ± 55 mL/min.

Table 1. Demographic and clinical characteristics of Patients

Patient

Age

Sex

Prior CKD

DM

HTN

HD
initiation
post
LVAD
implantation
(days)

1

70

M

Yes

Yes

Yes

24

3

Yes

DT

Deceased

2A

26

M

No

No

No

185

10

Yes

BTT

Alive with LVAD

2B

26

M

No

No

No

225

16

Yes

BTT

Alive/LVAD Explant

3

51

M

No

No

No

6

65

Yes

DT

Deceased

4

44

F

No

No

Yes

67

60

No

DT

Deceased

5

68

F

No

No

Yes

5

1

No

DT

Deceased

6

56

M

Yes

Yes

Yes

5

37

Yes

BTT

Alive/Transplant

7

41

M

No

No

Yes

16

57

No

DT

Deceased

8

41

M

No

No

No

109

42

Yes

BTT

Alive/Transplant

9A

83

M

Yes

No

Yes

15

22

Yes

DT

Alive with LVAD

9B

83

M

Yes

No

Yes

443

42

No

DT

Deceased

Days on
HD with
LVAD

Renal Function
Recovered

BTT/DT
*

Final Status

*BTT – Bridge to Transplant; DT – Destination Therapy

In the 9 reported patients there were 11 defined hemodialysis periods as patient
#2 and patient #9 had two distinct time frames on IHD that were separated by 1
and 13 months respectively. On average, patients received 16 ± 13 IHD
treatments, with a median of 11 sessions. The average hemodialysis prescription
across all 9 patients was 3.12 ± 0.3 hours and 1.98 ± 1.5 liters of UF. Actual
achieved dialysis therapy duration was 2.86 ± 0.9 hours and UF was 1.90 ± 1.6
liters (Table 2).
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Table 2. Hemodialysis Characteristics per Patient

Patient

# HD
Sessions

Average HD
Duration
Prescribed
(hrs)

Average HD
Duration
Achieved
(hrs)

# of Early
Termination
(%)*

Average
Prescribed UF
(L)

Average Net
UF (L)

# of HD
sessions with
UF not
achieved (%)**

1

3

3.0

3.0

0 (0%)

0.7

0.7

0 (0%)

2A

5

3.0

2.3

3 (60%)

1.8

1.6

2 (40%)

2B

7

2.9

2.9

0 (0%)

0.5

0.7

0 (0%)

3

32

3.4

3.4

1 (3%)

2.4

2.3

9 (28%)

4

33

3.2

3.2

2 (6%)

4.6

4.5

7 (21%)

5

1

2.5

0.5

1 (100%)

1.5

0.5

1 (100%)

6

17

3.6

3.5

1 (6%)

0.3

0.3

1 (6%)

7

32

3.5

3.4

3 (9%)

4.3

4.3

4 (13%)

8

21

3.2

3.2

0 (0%)

2.9

2.9

1 (5%)

9A

8

3.2

3.3

0 (0%)

2.8

2.8

0 (0%)

9B

11

3.0

3.0

0 (0%)

0.9

0.9

2 (19%)

* Number of HD treatments that were terminated ≥ 15 minutes before the end of the
prescribed HD duration (percent of all treatments that were terminated early).
** Number of HD treatments when the patient did not achieve ≥ 250 mL of the prescribed
UF (percent of all treatments)

Of the total 170 IHD treatments, LVAD parameters did not reveal any low-flow
event (as defined by PI) and only one of the 170 sessions was terminated due to
LVAD alarm. Nausea or emesis was experienced in 1.9 % of the IHD sessions.
The most common intervention for hemodynamic instability events was the
administration of albumin, which was primarily given for hypotension. There were
11 sessions (6.5%) when dialysis was terminated early. Early termination (ET) was
defined as those sessions when IHD was terminated ≥ 15 minutes before the end
of the prescribed IHD duration. On average, ET sessions were reduced by 60
minutes and varied in time post-LVAD implantation from 5-191 days (Table 3).
Causes of ET were hypotension in 72.7%, other causes were equally distributed
between clotted dialysis, nausea & vomiting and LVAD alarm (9.1% in each)
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(Table 3). Failure to achieve the prescribed UF by ≥ 250 mL occurred in 27 of the
170 sessions (15.9%) and averaged roughly 1,000 mL (Table 2).
Table 3. Detailed analysis of early terminated hemodialysis sessions

Patient

# of Early
Terminations
Per Patient

Reduced HD
Time (min)

Time since
LVAD
Insertion
(days)

2A

T1

60

185

Asymptomatic Hypotension

T2

90

189

Symptomatic Hypotension

T3

60

191

Asymptomatic Hypotension

3

T1

15

14

Clotted Dialyzer

4

T1

30

103

Asymptomatic Hypotension

T2

30

115

Nausea and Vomiting

5

T1

120

5

Symptomatic Hypotension

6

T1

105

17

LVAD Alarm

7

T1

30

50

Symptomatic Hypotension

T2

45

62

Symptomatic Hypotension

T3

120

66

Symptomatic Hypotension

Reason of HD Termination

Inability to register BP using standard sphygmomanometer due to LVAD-induced
reduction in pulse pressure was observed in 6 of the 9 patients at some point
throughout the course of their IHD sessions. During these episodes patients were
mostly asymptomatic with minimal increase in HR or cardiac rhythm changes
(assessed by telemetry monitoring) and had no change in mental status.
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Discussion
This retrospective study details the hemodialysis parameters and overall
tolerability in patients with LVAD requiring post-implantation IHD. There were very
few reported adverse events and ET of dialysis occurred in less than 10% of
treatments. The majority of patients achieved the prescribed ultrafiltration. All
patients that were BTT recovered kidney function prior to transplantation.
All but 1 of the patients included in this study were monitored while receiving IHD
within the ICU. This allowed for more frequent cardiac monitoring in addition to the
availability of inotropic agents. Although a MAP < 60 mmHg was experienced at
some point through the course of IHD for each patient (on average 48% of the
time) the intensive monitoring and availability of cardiac vasopressors allowed for
largely uneventful IHD sessions.
A minor portion of sessions requiring ET or adjustment of dialysis were mainly due
to episodes of asymptomatic hypotension. Hypotension in dialysis is multifactorial
with an underlying pathophysiology that includes diminished cardiac reserve, rapid
fluid removal, and autonomic neuropathy [11, 12]. The reported incidence of
symptomatic hypotension in the general IHD population during or shortly after
dialysis ranges from 15% to 50% of sessions [13]. Although hypotension was
frequently observed in our cohort of patients, it rarely required early IHD
termination. In addition, LVAD monitoring parameters did not reveal any low-flow
event and only one of the 170 sessions was terminated due to LVAD alarm. These
results corroborate other retrospective data by Quader, et al and Borrios, et al who
reported similar rates and types of adverse events [14, 15].
The continuous-flow nature of the LVAD’s, such as the Heartmate II, has the
potential to affect the measurement of both automated and manual cuffs. This is in
large part due to a reduction in pulse pressure via a constant increase in diastolic
BP generated by the pump [9]. In addition, many cardiovascular and pump related
factors, including but not limited to left ventricular contractility, intravascular
volume, preload, afterload, and pump speed are known to influence pulse
pressure [16]. The literature has described reduced accuracy in automatic BP
machines in comparison to other methods, such as invasive monitoring and
Doppler, in patients with continuous-flow devices. However, if a significant amount
of residual pulse pressure remains from the native left ventricle (LV) to allow pulse
pressure to remain above 12.8 ± 4.8, and therefore add pulsatility to the
continuous-flow provided by the LVAD, automatic BP machines have the ability to
measure both the systolic and diastolic pressures [9]. Birks et al. demonstrated
both an improvement in hemodynamic indices after LVAD implantation, likely, due
to myocardial remodeling from a reduction in the neuroendocrine response that
corresponds to HF [17]. This was echoed with a study that showed both an
increase in LV function on echocardiography and a reduction in plasma
catecholamine levels [18]. Thus, with extended periods of time, recovered cardiac
function should provide increased native LV function to produce pulse pressure
gradients detectable by an automated sphygmomanometer. For this reason,
automatic BP machines were utilized along with Doppler assessment of MAP.
Inability to register BP using standard sphygmomanometer due to LVAD-induced
reduction in pulse pressure was a common occurrence and observed in 6 of the 9
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patients at some point throughout the course of their IHD sessions. Again, during
these episodes patients were largely asymptomatic and had no change in their
mental status.
The most common intervention within the defined hemodynamic instability events
was the administration of albumin, which was primarily given for hypotension. This
often occurred in the absence of any documented symptoms of hypoperfusion.
Although this was the most common intervention in our study it is noteworthy;
however, that in one randomized controlled trial of maintenance hemodialysis
patients, the use of 5% albumin was not superior to normal saline for the treatment
of intradialytic hypotension [19]. Thus, although this was the primary intervention
used in this study in the inpatient setting, equal efficacy alternatives are available
for use in other centers and outpatient facilities. The albumin was used in this
study due to concerns for potential volume overload if normal saline was used.
Although normal saline is frequently used in outpatient centers, its use has not
been evaluated in LVAD patients.
In this study, the prescribed UF and IHD duration were achieved in the majority of
patients as IHD was terminated early in only 6.5% of IHD sessions. Nausea or
emesis was experienced in less than 2% of the IHD sessions, which in the general
IHD population can vary between 6 and 15% [20-22]. Mental status changes never
occurred in any of the IHD sessions in this study. Sinus tachycardia, defined as
HR > 100 bpm, was documented in 69 of the IHD sessions (41%). In the general
IHD population, incidence of cardiac arrhythmias varies between 18-76% [22-27],
and although the literature shows that ventricular arrhythmias are common in this
patient population [28], no serious arrhythmias were encountered in this study.
One-third of patients in this study had CKD prior to their LVAD implant. It is
interesting to note that Hasin et al. observed an improved glomerular filtration rate
after LVAD implantation in patients with CKD with abnormal renal function
secondary to decreased perfusion [29].
Out-patient dialysis centers are very cautious to accept end stage renal disease
patients with LVADs because of the potential complications and absence of
pulsatile blood pressure for monitoring. Many patients have to stay in the hospitals
for long time because of the unacceptance by the out-patient dialysis centers.
Based on our findings and Quader et al. study [14] it appears that patients with
LVAD are likely to tolerate out-patient in-center HD. However, specific protocols
and defined parameters to adhere to are needed to be developed and assessed.
Limitations of this study include those related to any retrospective analysis. The
most notable, was the reliance on IHD nurse documentation. Although unlikely,
symptoms, hemodynamic parameters, UF rate, or specific interventions may not
have been recorded accurately. A sample of 9 patients receiving a total of 170
hemodialysis sessions may not adequately reflect the true incidence of
hemodynamic events, symptomatic episodes, or need for therapeutic interventions
in this patient population.
Considerations for future investigation include the prospective evaluation of
patients with LVAD and direct comparison of their hemodynamic profile to other
patients receiving IHD. In addition, the efficacy of common strategies to minimize
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hypotension during IHD has not yet been investigated in LVAD patient population.
In particular, it is important to compare the effect of albumin to saline infusion, as
albumin is not commonly used in outpatient in-center dialysis units.
Conclusion
Patients with LVAD appear to tolerate in-hospital IHD relatively well compared to
non-LVAD patients. Symptoms of hemodynamic instability are rare and
hypotensive episodes are readily responsive to traditional interventions. Further
longitudinal studies are needed to assess whether with proper monitoring these
patients can tolerate outpatient IHD well.
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